eGenesis logo

eGenesis

eGenesis is a biotechnology company that uses genome engineering to develop pig organs designed to be compatible with human transplant recipients.

Checked 14 November 2026. Source

ShareLink copied

The record

Vertical
Pharma & Drug Discovery
Sub-segment
Gene edited organs for transplant
Product type
Therapeutics
Stage
Series C+
Headquarters
Cambridge, Massachusetts
Region
North America
Founded
2015

What they do

eGenesis was founded in 2015 and is based in Cambridge, Massachusetts. Its lead candidate is a donor kidney from a pig with three classes of genetic edits: removing genes linked to immediate rejection, adding seven human genes that help regulate immune and clotting responses, and inactivating viruses carried in the pig genome. In March 2024 a team at Massachusetts General Hospital performed the first transplant of an eGenesis kidney into a living patient under FDA expanded access. The company also has programs in acute liver failure and heart transplant. It raised a $191 million Series D in September 2024 led by Lux Capital.

Leadership & founders

Leadership as of 14 November 2026.

Source

Investors

In The HealthTech Signal

Related companies

Is this your company? Get a Verified profile